Trademark: NEUMORA 2244107
Word
NEUMORA
Device Descrption:
BRAIN,STYLISED
ID
2244107
Trademark Type
Figurative
Status
Registered: Registered/protected
Application Date
22 January 2022
Registration Date
22 January 2022
Renewal Date
22 January 2032
Owner(s)
Service
Ashurst Australia
Goods and Services:
Class 5:
Pharmaceutical preparations and substances for the treatment, management and prevention of neurological diseases and disorders, psychiatric diseases and disorders, central nervous system conditions, brain disorders and sleep disorders.
Pharmaceutical preparations and substances for the treatment, management and prevention of neurological diseases and disorders, psychiatric diseases and disorders, central nervous system conditions, brain disorders and sleep disorders.
Class 42:
Research and development of pharmaceutical preparations and substances for the treatment, management and prevention of neurological diseases and disorders, psychiatric diseases and disorders, central nervous system conditions, brain disorders and sleep disorders; Analyzing genetic, genomic, biological and clinical data for scientific research purposes; Analyzing genetic, genomic, biological and clinical data for the research and development of pharmaceuticals for treating neurological diseases and disorders, psychiatric diseases and disorders, central nervous system conditions, brain disorders and sleep disorders via targeted drug therapies.
Research and development of pharmaceutical preparations and substances for the treatment, management and prevention of neurological diseases and disorders, psychiatric diseases and disorders, central nervous system conditions, brain disorders and sleep disorders; Analyzing genetic, genomic, biological and clinical data for scientific research purposes; Analyzing genetic, genomic, biological and clinical data for the research and development of pharmaceuticals for treating neurological diseases and disorders, psychiatric diseases and disorders, central nervous system conditions, brain disorders and sleep disorders via targeted drug therapies.